Table 1.
Baseline characteristics of the study population with successfully measured Lp(a) levels
| Characteristic | Cases (n = 1850) | n (%) missing data |
|---|---|---|
| Female sex, n (%) | 857 (46%) | 1 (0.1%) |
| Age (years) | 65.20 (10.54) | 1 (0.1%) |
| Age of onset diabetes (years) | 54.94 (11.71) | 118 (6%) |
| Duration of diabetes (years) | 10.02 (8.40) | 118 (6%) |
| Duration of follow-up (years) | 6.97 (2.10) | 11 (0.6%) |
| BMI, (kg/m2) | 29.50 (27.00–33.05) | 129 (7%) |
| HbA1c (mmol/mol) | 50.82 (45.46–59.57) | 92 (5%) |
| HbA1c (%) | 6.80 (6.30–7.60) | 92 (5%) |
| MAP (mmHg) | 98.97 (10.80) | 126 (7%) |
| Total cholesterol (mmol/l) | 4.29 (0.93) | 90 (5%) |
| Triacylglycerols (mmol/l) | 1.43 (1.02–2.04) | 92 (5%) |
| HDL-cholesterol (mmol/l) | 1.10 (0.93–1.32) | 93 (5%) |
| Non-HDL-cholesterol (mmol/l) | 3.12 (0.90) | 93 (5%) |
| LDL-cholesterol (mmol/l) | 2.45 (0.83) | 120 (6%) |
| Lp(a) (mg/dl) | 27.40 (42.09) | 0 |
| Lp(a) (mg/dl) | 11.00 (5.00–31.55) | 0 |
| Lp(a) ≥30 mg/dl, n (%) | 483 (26%) | 0 |
| Creatinine (μmol/l) | 77.00 (67.00–92.00) | 121 (7%) |
| eGFR (MDRD) (ml min–1 [1.73 m]−2) | 77.36 (22.48) | 121 (7%) |
| Outpatient clinic patients, n (%) | 796 (43%) | - |
| Smoking, n (%) | 177 (10%) | |
| Never | 433 (26%) | |
| Former | 943 (56%) | |
| Current | 297 (18%) | |
| Microvascular complications at baseline | ||
| Retinopathy at baseline, n (%) | 298 (17%) | 105 (6%) |
| Nephropathy at baseline, n (%) | 375 (23%) | 199 (11%) |
| Neuropathy at baseline, n (%)a | 223 (31%) | 1118 (60%) |
| Microvascular complications during follow-up | ||
| Retinopathy during follow-up, n (%) | 223 (16%) | 156 (8%) |
| Nephropathy during follow-up, n (%) | 246 (19%) | 107 (6%) |
| Neuropathy during follow-up, n (%)a | 236 (32%) | 1123 (61%) |
Unless stated otherwise, mean (±SD) are given for normally distributed covariates. For non-normally distributed covariates, median and IQR are given
aInformation only available for individuals who attended an outpatient clinic (n = 796)